RxDoctor Payments Data

Ruslan Garcia, MD

Internal Medicine · Murphy, NCNPI 1659802445

Payments from drug & device makers

$2,469in general payments, 2019–2025

Across 110 payments — averaging $22.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$294
  • GSK$152
  • Lilly USA, LLC$135
  • Amgen$120
  • Bayer$116
  • plus $454 from 9 others

What the payments were for

  • Food & beverage$2,469100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,469 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$18,417
Medicare patients
122
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$181,899
Enbrel SureclickEtanercept23$166,921
MounjaroTirzepatide74$104,134
JardianceEmpagliflozin55$78,237
XareltoRivaroxaban58$61,450
Repatha SureclickEvolocumab49$52,739
BiktarvyBictegrav/Emtricit/Tenofov Ala13$48,650
EntrestoSacubitril/Valsartan45$43,112
EliquisApixaban37$37,911
TrulicityDulaglutide13$30,730
Synjardy XrEmpagliflozin/Metformin Hcl24$24,200
Humalog Kwikpen U-200Insulin Lispro17$22,192
Tresiba Flextouch U-100Insulin Degludec31$21,859
FarxigaDapagliflozin Propanediol14$18,484
Tresiba Flextouch U-200Insulin Degludec16$17,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$294$181,89999 claims
Lilly USA, LLCMounjaro, Trulicity$135$134,86387 claims
Johnson & JohnsonXarelto$31$61,45058 claims
GileadBiktarvy$19$48,65013 claims
NovartisEntresto$68$43,11245 claims
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix$152$29,45456 claims
AstraZenecaFarxiga, Brilinta$107$23,15325 claims
AbbVieLinzess$1,199$8,69514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Murphy

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →